BEST4 (Gene)

Organism:

Homo sapiens

Synonyms:BEST4, ENTREZ:266675, HGNC:17106, MIM:607336, NM_153274, NP_695006, VMD2L2, XM_017001022, XM_017001023, XM_024446367, XP_016856511, XP_016856512, XP_024302135, bestrophin 4

Id:ENSG00000142959

Entrez:266675

Ensembl:ENSG00000142959

Description:bestrophin 4

This gene is a member of the bestrophin gene family of anion channels. Bestrophin genes share a similar gene structure with highly conserved exon-intron boundaries, but with distinct 3' ends. Bestrophins are transmembrane proteins that contain a homologous region rich in aromatic residues, including an invariant arg-phe-pro motif. Mutation in one of the family members (bestrophin 1) is associated with vitelliform macular dystrophy. The bestrophin 4 gene is predominantly expressed in the colon. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View BEST4's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with BEST4.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using BEST4.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for BEST4.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with BEST4.

Results found

Linked to

	Label	Description
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE189035 inositol 2 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 3 V 5 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 0 V 5 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE103567 EZH2 inhibition 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE148200 0 V 2 GEMCITABINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 cisplatin 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE189035 inositol 2 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE189035 inositol 2 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 7 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE148200 3 V 5 GEMCITABINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE148200 0 V 5 GEMCITABINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE103567 EZH2 inhibition 5 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.